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Patients’ views on fecal microbiota transplantation:
an acceptable therapeutic option in inﬂammatory
bowel disease?
Jonas Zeitza,*, Marina Bissiga,b,*, Christiane Barthele, Luc Biedermanna, Sylvie Scharla, Daniel Pohla, Pascal Freia,d,
Stephan R. Vavrickaa,c, Michael Frieda, Gerhard Roglera and Michael Scharla
Background Fecal microbiota transplantation (FMT) represents a new therapeutic option that has been studied in two
randomized-controlled trials in ulcerative colitis patients. Our study aimed to identify patients’ views on the use of this novel
therapeutic approach.
Methods Using an anonymous questionnaire, we obtained data from 574 inﬂammatory bowel disease (IBD) patients on their
knowledge and willingness to undergo FMT.
Results A large proportion of IBD patients (53.5%) are unaware that FMT is a therapeutic option in Clostridium difﬁcile infection
and potentially IBD. More responders preferred FMT (31.5%) to a study with a new medication (28.9%), although the difference
was not signiﬁcant (P=0.37), and the preferred way of transplantation was colonoscopy (49.7%). In all, 38.3% preferred a family
member as a donor, but there was fear about the procedure (41.5% mentioned fear of infectious diseases, 26.5% expressed
disgust). The knowledge of successful FMT treatment in other patients was important for 82.2% of responders and for 50.7%, a
discussion with a specialist would likely change their opinion about FMT.
Conclusion FMT represents a therapeutic procedure that is of interest for IBD patients. As FMT has been receiving increasing
interest as an alternative treatment in IBD and more studies on FMT in IBD are being carried out, it is important to learn about the
knowledge, attitude, and preferences of patients to provide better education to patients on this topic. However, there are
reservations because of the fact that data on the beneﬁts of FMT in IBD are controversial and several limitations exist on the use of
FMT in IBD. Eur J Gastroenterol Hepatol 29:322–330
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Introduction
Environmental, genetic, and immunological factors as well
as the intestinal microbiota have been considered to be
major etiological factors in the pathogenesis of inﬂam-
matory bowel disease (IBD) [1]. Evidence suggests that the
development of IBD is a result of an inappropriate and
ongoing activation of the mucosal immune system driven
by the presence of intestinal microbiota in the genetically
susceptible host [2–4].
Besides IBD, infectious diseases of the bowel are also
associated with diarrhea and abdominal pain. One
example is Clostridium difﬁcile infection (CDI). Bartlett
et al. [5] ﬁrst identiﬁed C. difﬁcile as the major infectious
cause of antibiotic-associated diarrhea in 1978. In the past
few years, there has been a constant increase in CDI [6].
The treatment of choice is an antibiotic treatment with
metronidazole or vancomycin, with clinical cure rates of
90%. An emerging therapeutic option for the treatment of
CDI in recent years is fecal microbiota transplantation
(FMT) and treatment guidelines have been published [7,8].
In a randomized study by van Nood et al. [9], the infusion
of donor feces was signiﬁcantly more effective for the
treatment of recurrent CDI than the use of vancomycin.
Because of the high efﬁcacy of this treatment and the
relatively low rate of adverse effects, FMT has gained
increasing importance in the treatment of recurrent
C. difﬁcile colitis, with several randomized trials con-
ducted in the past few years showing its efﬁcacy [10–12].
In FMT, a fecal suspension from a healthy individual is
infused into the gastrointestinal tract of another individual
in an attempt to treat an illness. This treatment has a low
complication rate; adverse effects that are most often
reported are those associated with a colonoscopy.
Furthermore, to date, no transmissions of infectious bowel
diseases have been reported [13].
CDI has also become particularly problematic for
patients with IBD, contributing to a signiﬁcant burden of
disease [14]. The prevalence of asymptomatic Clostridium
carriage in IBD is higher and the incidence of symptomatic
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CDI has been increasing [15–17]. Furthermore, patients
with IBD are at an increased risk for adverse outcomes
from CDI, which can also impact the management of the
underlying IBD [18]. In a recent retrospective cohort study
by Razik et al. [19], where IBD patients with recurrent CDI
were compared with those with a single episode, IBD
patients were 33%more likely to experience recurrent CDI
compared with the general population.
In terms of the therapy of IBD, the management of an
acute ﬂare and the maintenance of remission have to be
distinguished and therapeutic options in IBD treatment
include medical as well as surgical interventions [20,21]. In
both settings, systemic immunosuppressive medications,
such as corticosteroids or anti-tumor necrosis factor (TNF)
antibodies, play an important role. However, the success
of all of these therapeutic options is limited in a signiﬁcant
number of patients and severe side effects can occur
[20,21]. Furthermore, ulcerative colitis (UC) and Crohn’s
disease (CD) account for considerable and growing costs
to the healthcare system and society [22]. In a German
study, it was shown that in the outpatient setting, drugs
accounted for 85% of the total costs [23]. Therefore, the
need for novel, highly efﬁcient, and well-tolerable treat-
ment options is obvious.
Current research has led to more and more interest on
FMT for the treatment of IBD. However, data on the use of
FMT in IBD are sparse, but since a ﬁrst case report of FMT
for UC treatment by Bennet and Brinkman [24] was pub-
lished in 1989, this therapeutic option has been studied
more widely. Still, the data on the beneﬁts of FMT in UC
are controversial and there are no data supporting the use
of FMT in CD. In detail, Kunde et al. [25] carried out a
single-center uncontrolled study of FMT in 10 children
with UC, showing safety, tolerability, and clinical response.
However, because of the small sample size and the short
follow-up period of only 6 weeks, the results have to be
interpreted with caution. In a recent systematic review by
Ianiro et al. [26], summarizing the results of 133 patients
with IBD who were managed with FMT, a resolution of or
a reduction in symptoms was reported in 80 (71%) of 113
patients with evaluable IBD. Furthermore, recently, two
randomized-controlled trials evaluated FMT in UC. In a
randomized-controlled trial conducted by Moayyedi et al.
[27], comparing FMT and placebo in active UC, of 70
patients, nine (24%) of 38 patients who received FMT and
two (5%) of 37 patients who received placebo were in
remission at 7 weeks, showing a statistically signiﬁcant
effect of FMT (P=0.03), with no difference in adverse
events. However, in a randomized-controlled phase 2 trial
by Rossen and colleagues, comparing FMT from healthy
donors to autologous fecal microbiota (control) in 50
patients with mild to moderately active UC, there was no
statistically signiﬁcant difference in clinical and endoscopic
remission between the two groups. However, this may be
because of the limited number of patients who were
included in the study [28].
However, there are still several limitations in the use of
FMT in IBD, but there is no standardization of FMT
preparation and the ideal route and timing/duration of
administration to induce and maintain a clinical response
has to be further investigated. Also, the optimal choice of
the donor is still unclear. Further, the use of FMT is limited
to CDI by the American Food and Drug Administration;
apart from CDI, an investigational new drug permit is
required. FMT in IBD is also mentioned in the current
international IBD treatment guidelines [20,29,30].
Despite the interest in FMT in IBD patients, this treat-
ment approach is still underinvestigated. This is also
because of the fact that respective research is restricted by
regulatory agencies mainly because of concerns about the
potential risks of FMT [31–34]. Further, there are no
conclusive data available on whether patients would even
tolerate FMT as a treatment. However, patients are
actively asking for this type of treatment and, in particular,
on the internet, there are ‘do-it-yourself’ home protocols
for FMT and reports on patients’ own FMT experiences
performed by themselves [35,36].
Two recent studies suggested that patients would
actually be very interested in performing FMT in a hospital
setting as a treatment for their IBD [37,38]. Here, we
aimed to assess the view of a broad number of IBD patients
with respect to FMT as a potential treatment option.
Methods
Study design
The study was approved by the local ethical committees
(approval number: KEK-ZH-Nr. 2013-0493 from 5
November 2013, Cantonal Ethics Committee of the
Canton Zürich, Switzerland). The data were collected and
analyzed anonymously. Patients were entirely recruited
from Swiss Crohn’s Disease and Ulcerative Colitis Patient
Network (SMCCV). The SMCCV is an IBD support group
with members from all parts of Switzerland. It currently
includes 2237 members (which includes patients but also
gastroenterologists and companies); 1828 are IBD
patients. A total of 747 patients with UC and 1081
patients with CD are registered. In all, 1328 are female and
855 are male members. The study was carried out using an
anonymous questionnaire that was developed speciﬁcally
for this purpose. Patients who went through FMT were
not excluded from the study/analyses.
Survey instrument
An anonymous questionnaire was sent to the patients of
the SMCCV. An anonymous questionnaire was developed
speciﬁcally for this purpose. To aid the development of the
questionnaire, patient interviews in the IBD clinic of the
University Hospital Zurich were performed.
At the beginning of the administration of the ques-
tionnaire, before they read an information sheet about FMT,
patients were ﬁrst questioned whether they had heard about
FMT in the past and whether they would undergo FMT on
the basis of their current state of knowledge (before reading
the FMT information page, see Supplemental digital content
1, http://links.lww.com/EJGH/A146, Supplemental digital
content 2, http://links.lww.com/EJGH/A147). Then, an A4
page of basic information on FMT was provided to the
patients (for English translation of information sheet, see
Supplementary Appendix, Supplemental digital content 3,
http://links.lww.com/EJGH/A148). As the questionnaire
was sent out by post, it could not be veriﬁed whether the
patients read the FMT information page before answering
the ﬁrst questions. This was followed by questions on
patients’ demographics (year of birth, age at diagnosis, sex),
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disease characteristics (type of IBD, complications such as
ﬁstula and/or bowel stenosis, history of surgery, history of
medical therapy, course of the disease), their knowledge of
FMT, and their views about undergoing FMT. Question
formats included yes or no questions and multiple-choice
questions. At the end of the questionnaire, the patients were
again questioned whether they would agree to undergo
FMT.
Statistical analysis
A descriptive statistical analysis was carried out. Qualitative
variables were expressed as percentages, whereas quantita-
tive variables were expressed as median. Furthermore, a
statistical analysis was carried out using a two-sided Fisher’s
exact test (GraphPad Prism 5.04 for Windows; GraphPad
Software Inc., La Jolla, California, USA).
Results
Patients’ characteristics
A total of 2237 questionnaires were sent out (to all
SMCCV members); only IBD patients were asked to
complete the questionnaires (1828 patients). In total, we
received 574 completed questionnaires, yielding a response
rate of 31.4%.
Responders ranged in age from 14 to 86 years (median:
46 years). Seven patients were below 18 years of age at the
time of the study. The median age at diagnosis was 29 years
(1–83 years). Overall, 334 (58.2%) responders were
females and 239 (41.6%) responders were males. In terms
of the disease characteristics, 327 (56.9%) responders had
CD, 234 (40.8%) responders had UC, and 13 (2.2%)
responders did not specify what disease they had (Table 1).
In terms of previous history of surgery because of IBD,
383 (66.7%) responders had never undergone surgery and
187 (32.6%) responders had undergone one or more sur-
gical procedures in the past. The self-reported disease
severity was mild in 200 (34.9%) responders, moderate in
279 (48.6%) responders, and severe in 77 (13.4%)
responders; 18 (3.1%) responders did not specify. When
questioned on their quality of life, the majority of responders
(370 responders, 64.4%) stated that their disease negatively
inﬂuenced their daily activities, whereas in 192 (33.5%)
responders, it did not. When asked to what extent the
responders worried about the future course of their disease,
the majority of responders (342 responders, 59.6%) worried
at least a little about possible disease progression, 168
(29.3%) responders did not worry, and 61 (10.6%)
responders reported considerable fear that the disease may
progress. Furthermore, 72.1% of the responders (414
responders) reported worries about possible side effects of
actual or future medical treatment, whereas only 154
(26.8%) responders were not worried (Table 1).
Questions on fecal microbiota transplantation
A roughly equal fraction of responders had never heard of
FMT (307 responders, 53.5%), whereas 262 (45.6%)
responders were aware of FMT. In all, 55.4% of the
responders (318 responders) stated that they would not
undergo FMT on the basis of their current state of
knowledge, whereas 36.9% (212 responders) would agree
to the procedure. In all, 44 (7.7%) responders did not
answer the question (Table 1). When comparing CD ver-
sus UC responders, 114 of 327 CD responders and 97 of
234 UC responders stated that they would agree to FMT
on the basis of their current state of knowledge, with no
statistically difference between the two groups [P=0.12,
odds ratio (OR)=0.75, 95% conﬁdence interval (CI):
0.52–1.06]. Also, on comparing men versus women
(OR= 1.15, 95% CI: 0.81–1.64, P=0.47), mild versus
severe disease (OR=0.65, 95% CI: 0.37–1.12, P=0.12),
and TNF-naive versus TNF-experienced responders
(OR= 1.10, 95% CI: 0.75–1.61, P= 0.70), there was no
statistically signiﬁcant difference.
When further asked about their preference between a
study with a new medication or FMT, 166 (28.9%)
responders preferred a study with a new medication, 181
(31.5%) responders preferred FMT, 226 (39.4%)
responders were not sure about what to choose, and 17
(3%) responders did not answer the question (multiple
answers possible).
We were next interested in which donor the patients
would accept. The majority of responders (220 responders,
38.3%) stated that they would prefer a family member for
FMT, 190 (33.1%) responders stated that they would
choose the spouse/living partner, only 7% (40 responders)
stated that they would pick a friend, and 35.2% (202
responders) stated that they did not care about the kind of
donor. In this question, multiple answers were possible.
When asked what concerns the patient has regarding FMT
(multiple answers possible), 238 (41.5%) responders men-
tioned fear of infectious diseases, 152 (26.5%) responders
expressed disgust about the procedure, 139 (24.2%) respon-
ders stated that the estimated success rate is too low, and 147
(25.6%) responders did not know what would speak against
fecal transplantation. In all, 27 (4.7%) responders did not
specify.
On being asked whether their decision would be inﬂu-
enced in a positive way if they would know about suc-
cessful FMT treatment in other patients, 472 (82.2%)
responders answered that they agreed, 85 (14.8%) dis-
agreed, and 17 (3%) responders did not specify.
Overall, 291 (50.7%) responders stated that a detailed
discussion with a specialist would probably change their
opinion about FMT, whereas 64 (11.2%) responders sta-
ted that this would not change their opinion and 204
(35.5%) were undecided. In all, 15 (2.6%) did not answer
the question.
For the majority of responders, the preferred way of
transplantation would be colonoscopy (285 responders,
49.7%), 120 (21%) responders stated that they would
choose an enema, and only 29 (5.1%) responders stated
that they would choose application of the FMT by naso-
gastric tube (NGT) placement. In all, 155 (27%) respon-
ders had no preferred route of application and 34 (5.9%)
did not answer the question. In this question, multiple
answers were possible.
Patients were then questioned whether, if they do agree
to a FMT, they would then also agree to receive FMT by
one or multiple anonymous donors. Overall, 184 (32.0%)
stated that they would agree to anonymous donor(s), 181
(31.5%) stated that they would not, and 197 (34.3%)
were undecided. In all, 12 (2.1%) responders did not
answer the question.
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Table 1. Results of the questionnaire
Questions
All responders
[n (%)]
Crohn’s disease
[n (%)]
Ulcerative colitis
[n (%)]
1. Did you hear about the possibility of FMT in the past? (question before FMT information sheet)
Yes 262 (45.6) 141 (43.1) 117 (50)
No 307 (53.5) 185 (56.6) 114 (48.7)
Not speciﬁed 5 (0.9) 1 (0.3) 3 (1.3)
Total 574 (100) 327 (100) 234 (100)
2. Would you undergo FMT at your current level of knowledge? (question before FMT information sheet)
Yes 212 (36.9) 114 (34.9) 97 (41.5)
No 318 (55.4) 189 (57.8) 120 (51.3)
Not speciﬁed 44 (7.7) 24 (7.3) 17 (7.2)
Reading of FMT information sheet
3. Sex
Male 239 (41.6) 197 (60.2) 131 (56)
Female 334 (58.2) 130 (39.8) 103 (44)
Not speciﬁed 1 (0.2%) – –
4. Age (years) 46 (14–86) – –
5. Diagnosis
Crohn’s disease 327 (57) – –
Ulcerative colitis 234 (40.8) – –
Not speciﬁed 13 (2.2) – –
6. Age at diagnosis (years)
Median (range) 29 (1–83) – –
7. Previous surgeries due to IBD?
No 383 (66.7) 166 (50.1) 207 (88.5)
1× 75 (13.1) 68 (28.7) 7 (3)
2× 41 (7.1) 30 (9.2) 11 (4.7)
3× or more 71 (12.4) 61 (18.7) 8 (3.4)
Not speciﬁed 4 (0.7) 2 (0.6) 1 (0.4)
8. Which are the current or former immunosuppressive medications you take/took?
Steroids
Yes 368 (64.1) 210 (64.2) 152 (65)
No 129 (22.5) 69 (21.1) 57 (24.4)
Not speciﬁed 77 (13.4) 48 (14.7) 25 (10.7)
Azathioprine/mercaptopurine/methotrexate
Yes 344 (59.9) 216 (66.1) 123 (52.6)
No 161 (28.1) 70 (21.4) 87 (37.2)
Not speciﬁed 69 (12) 41 (12.5) 24 (10.3)
Anti-TNF therapy (inﬂiximab/adalimumab/certolizumab-pegol)
Yes 214 (37.3) 149 (45.6) 62 (26.5)
No 255 (44.4) 127 (38.8) 123 (52.6)
Not speciﬁed 105 (18.3) 51 (15.6) 49 (20.9)
9. How would you describe the course of your disease?
Mild 200 (34.9) 111 (33.9) 85 (36.3)
Moderate 279 (48.6) 166 (50.8) 108 (46.2)
Severe 77 (13.4) 41 (12.5) 34 (14.5)
Not speciﬁed 18 (3.1) 9 (2.8) 7 (3)
10. Do you suffer from your disease and are you impaired in your daily life?
No 192 (33.5) 100 (30.1) 89 (38)
Yes, a little 290 (50.5) 173 (52.9) 112 (47.9)
Yes, a lot 80 (13.9) 50 (15.3) 27 (1.2)
Not speciﬁed 12 (2.1) 4 (1.2) 6 (2.6)
11. Do you fear of the further course of your disease?
No 168 (29.3) 99 (30.3) 68 (29.1)
Yes, a little 342 (59.6) 190 (58.1) 143 (61.1)
Yes, a lot 61 (10.6) 37 (11.3) 23 (9.8)
Not speciﬁed 3 (0.5) 1 (0.3)
12. Are you worried about the side effects of medication you are taking at the moment or you might have to take in the future?
No 154 (26.8) 87 (26.6) 63 (26.9)
Yes, a little 280 (48.8) 169 (51.7) 108 (46.2)
Yes, a lot 134 (23.3) 70 (21.4) 60 (25.6)
Not speciﬁed 6 (1.1) 1 (0.3) 3 (1.3)
13. Which of the following therapeutic options would you prefer? (multiple answers possible)
Study with a new
medication
166 (28.9) 92 (28.1) 71 (30.3)
Fecal transplantation 181 (31.5) 95 (29.1) 85 (36.3)
Don’t know 226 (39.4) 139 (42.5) 80 (34.2)
Not speciﬁed 17 (3) 9 (2.8) 6 (2.6)
14. Who would you choose as a FMT donor? (multiple answers possible)
Family member 220 (38.3) 131 (40.1) 87 (37.2)
Spouse/living partner 190 (33.1) 102 (31.2) 85 (36.3)
Friends 40 (7) 28 (8.6) 11 (4.7)
Doesn’t matter 202 (35.2) 111 (33.4) 87 (37.2)
Not speciﬁed 49 (8.5) 26 (8) 19 (8.1)
15. What would argue against FMT for you personally? (multiple answers possible)
Fear of infectious
disease
238 (41.5) 138 (42.2) 95 (40.6)
To less successful 139 (24.2) 89 (27.2) 49 (20.9)
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The patients were again asked whether they would
undergo FMT after reading the Information sheet about FMT
and after answering the previous 19 questions. The majority
of responders (345 from 574, 60.1%) agreed to FMT
[including 191 (33.3%) responders who agreed to FMT and
154 (26.8%) responders who would agree to FMT, but only
as the last therapeutic option], whereas 92 (16%) responders
stated that they would not. In all, 128 (22.3%) were unde-
cided and nine (1.6%) responders did not answer the ques-
tion. Interestingly, there was a change in the decision on FMT
(Fig. 1 and Table 1).
When comparing CD versus UC responders, 195 of 327
CD responders and 149 of 234 UC responders stated that
they would agree to FMT at the end of the questionnaire,
with no statistically difference between the two groups
(OR= 0.89, 95% CI: 0.55–1.43, P= 0.72). Also, when
comparing men versus women (OR=1.21, 95% CI:
0.76–1.94, P= 0.48) and patients with mild versus severe
disease (OR=0.71, 95% CI: 0.34–1.47, P= 0.38), there
was no statistically signiﬁcant difference. TNF-naive ver-
sus TNF-experienced responders were also compared
(Fig. 2).
This result was also analyzed in a subgroup analysis of
CD versus UC responders (Figs 3 and 4).
The majority of responders did not feel sure (282
responders, 49.1%) about their decision to undergo FMT,
whereas 255 (44.4%) felt sure with their decision and 37
(6.5%) responders did not specify.
In terms of the awareness of the advantages and dis-
advantages of FMT, 260 (45.3%) responders stated that
they were aware of the advantages and disadvantages,
whereas 278 (48.4%) stated that they were not. In all, 36
(6.3%) responders did not specify. Furthermore, the
majority of responders (289, 50.4%) stated that they were
sure about which advantages and disadvantages are the
most important for themselves, whereas 251 (43.7%)
responders stated that they were not. In all, 34 (5.9%)
responders did not specify.
Finally, the patients were asked whether they had
enough support and advice to make a decision about
FMT. Overall, 196 (34.1%) responders agreed that they
had enough support/advice for their decision, whereas 338
(58.9%) responders stated that they did not. In all, 40
(7%) responders did not specify (Table 1).
Table 1. (Continued)
Questions
All responders
[n (%)]
Crohn’s disease
[n (%)]
Ulcerative colitis
[n (%)]
Disgust 152 (26.5) 92 (28.1) 58 (24.8)
Don’t know 147 (25.6) 78 (23.9) 63 (26.9)
Not speciﬁed 27 (4.7) 15 (4.6) 10 (4.3)
16. Would your decision be inﬂuenced if you had knowledge about successful FMT therapies in other patients?
Yes 472 (82.2) 264 (80.7) 200 (85.5)
No 85 (14.8) 52 (15.9) 30 (12.8)
Not speciﬁed 17 (3) 11 (3.4) 4 (1.7)
17. Would a detailed discussion with a specialist change your opinion?
Yes 291 (50.7) 161 (49.2) 125 (53.4)
No 64 (11.2) 33 (10.1) 27 (11.5)
Don’t know 204 (35.5) 123 (37.6) 79 (33.8)
Not speciﬁed 15 (2.6) 10 (3.1) 3 (1.3)
18. Which of the following procedures for FMT would you prefer? (multiple answers possible)
Nasogastric tube 29 (5.1) 25 (7.6) 3 (1.3)
Colonoscopy 285 (49.7) 157 (48) 126 (53.8)
Enema 120 (21) 57 (17.4) 60 (25.6)
Doesen’t matter 155 (27) 95 (29.1) 56 (23.9)
Not speciﬁed 34 (5.9) 20 (6.1) 11 (4.7)
19. If you agree to FMT would you also agree to an anonymous donor/donors?
Yes 184 (32.0) 99 (30.3) 83 (35.5)
No 181 (31.5) 110 (33.6) 67 (28.6)
Don’t know 197 (34.3) 110 (33.6) 83 (35.5)
Not speciﬁed 12 (2.1) 8 (2.44) 1 (0.4)
20. Would you now undergo FMT with your actual state of knowledge?
No 92 (16) 53 (16.2) 36 (15.4)
Yes 191 (33.3) 101 (30.9) 89 (38)
Yes, as the last option 154 (26.8) 94 (28.7) 60 (26.6)
Don’t know 128 (22.3) 75 (22.9) 47 (20.1)
Not speciﬁed 9 (1.6) 4 (1.2) 2 (0.9)
21. Do you feel conﬁdent about your decision to possibly undergo FMT?
Yes 255 (44.4) 138 (42.2) 114 (48.7)
No 282 (49.1) 166 (50.8) 111 (47.4)
Not speciﬁed 37 (6.5) 23 (7) 9 (3.9)
22. Are you aware of the advantages and disadvantages of FMT?
Yes 260 (45.3) 141 (43.1) 117 (50)
No 278 (48.4) 164 (50.2) 106 (45.3)
Not speciﬁed 36 (6.3) 22 (6.7) 11 (4.7)
23. Are you aware of the advantages and disadvantages that are the most important for you?
Yes 289 (50.4) 161 (49.2) 127 (54.3)
No 251 (43.7) 145 (44.3) 98 (41.9)
Not speciﬁed 34 (5.9) 21 (6.4) 9 (3.8)
24. Did you get enough support and advise to make your decision?
Yes 196 (34.1) 111 (33.9) 83 (35.5)
No 338 (58.9) 197 (60.2) 134 (57.3)
Not speciﬁed 40 (7) 19 (5.8) 17 (7.3)
FMT, fecal microbiota transplantation; IBD, inﬂammatory bowel disease; TNF, tumor necrosis factor.
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Discussion
Using data from 574 patients of the SMCCV, we showed
that FMT might be accepted as a therapeutic option by
many IBD patients. The majority of the patients, 60.1%,
who took part in our survey stated that they would
undergo FMT, 44.6% of these only as the last therapeutic
option. Moreover, when questioned about their pre-
ferences between a study with a new medication or FMT,
more patients stated that they would prefer FMT (31.5%)
compared with a study with a new medication (28.9%),
although the difference was not signiﬁcant (OR= 0.88,
95% CI: 0.69–1.14, P= 0.37). This is of particular interest
and might be because of the fact that FMT might be
considered a ‘natural’ treatment with possibly foreseeable
side effects in contrast to the treatment with a novel, likely
‘unnatural’ molecule exerting possibly unforeseeable risks.
However, to date, the long-term effects after FMT are
not known.
Different routes of administrations for FMT are cur-
rently being studied (oral capsules, NGT, enema, or by
colonoscopy) [39,40]. To date, the best route of adminis-
tration has not been established. In terms of recurrent CDI,
a meta-analysis by Postigo and Kim [41] showed that
despite procedural differences, FMT by colonoscopy or
NGT appeared to be highly effective and safe for the
management of recurrent CDI, whereas other studies sug-
gested that lower gastrointestinal FMT delivery leads to a
trend toward higher clinical resolution rates than the upper
gastrointestinal route [42,43]. In IBD, no studies compar-
ing the different procedures have been carried out until
now. In our study, 49.7% of the responders chose colo-
noscopy as the preferred route, even though this procedure
was the most time consuming and complex, compared with
an application by NGT or enema. Only 5.1% stated that
they would choose application of FMT by NGT. This is
probably because the idea of receiving FMT by the oral
route is not appealing, which is underlined by the fact that
26.5% of the patients in our study expressed disgust about
the procedure as a reason for not receiving FMT. It has to
be noted that in some cases of IBD, some routes of delivery
may be more suitable (e.g. small intestinal CD). Because the
information sheet was only one page long and because of
the fact that such in-depth information would be beyond
the depth of information that can be passed on to some-
body by a short written information sheet, we did not
include this topic in the information sheet.
Fig. 1. The proportion of all responders agreeing to FMT before and after
reading the questionnaire. When comparing the view of patients on FMT at
the beginning versus the end of the questionnaire, at the end of the ques-
tionnaire, a signiﬁcantly higher proportion of all responders agreed to FMT
compared with the beginning of the questionnaire (345 vs. 212 responders)
(OR= 0.18, 95% CI: 0.13–0.24, P<0.0001). CI, conﬁdence interval; FMT,
fecal microbiota transplantation; OR, odds ratio.
Fig. 2. The proportion of TNF/TNF-naive responders agreeing to FMT after
reading the questionnaire. When comparing TNF-naive versus TNF-
experienced responders, statistically more TNF-experienced responders
stated that they would agree to FMT after reading the questionnaire com-
pared with responders without TNF therapy (OR=1.81, 95% CI: 1.05–3.12,
P=0.03). CI, conﬁdence interval; FMT, fecal microbiota transplantation; OR,
odds ratio; TNF, tumor necrosis factor.
Fig. 3. The proportion of UC responders agreeing to FMT before and after
reading the questionnaire. In a subgroup analysis of CD versus UC respon-
ders, in the UC group, signiﬁcantly more responders (149 of 234 responders)
stated that they would agree to FMT at the end of the questionnaire com-
pared with the beginning (97 of 234 responders) (OR=0.20, 95% CI:
0.12–0.31, P<0.0001). CD, Crohn’s disease; CI, conﬁdence interval; FMT,
fecal microbiota transplantation; OR, odds ratio; UC, ulcerative colitis.
Fig. 4. The proportion of CD responders agreeing to FMT before and after
reading the questionnaire. In a subgroup analysis of CD versus UC
responders, in the CD group, signiﬁcantly more responders (195 of 327
responders) stated that they would agree to FMT at the end of the ques-
tionnaire compared with the beginning (114 of 327 responders) (P< 0.0001,
OR=0.16, 95% CI: 0.41–0.56). CD, Crohn’s disease; CI, conﬁdence inter-
val; FMT, fecal microbiota transplantation; OR, odds ratio; UC, ulcerative
colitis.
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To date, there are no data available on what kind of
donor might be best for FMT in IBD patients. It is pro-
posed that the development of IBD is a result of an inap-
propriate and ongoing activation of the mucosal immune
system, driven by the presence of intestinal microbiota. In
our study, the majority of patients (38.3%) stated that they
would choose a family member. It is questionable whether
this is the best donor in the setting of IBD. For instance, it
is known that the microbiome is similar in co-habiting
individuals and family members [44,45]. In a recently
published randomized-controlled trial comparing FMT
and placebo in active UC, the kind of donor seemed to
affect the outcome of FMT. The study was carried out
with six different donors. Although a response rate of 7/18
(39%) was obtained for one single donor, the response
rate for the other donors was only 2/20 (10%). Also, there
was a statistically signiﬁcant effect of the active therapy
group being more similar to their donor than a control
fecal sample [27]. Therefore, transferring a very similar
intestinal microbiome might limit the success of FMT. The
fact that the kind of donor seems to have an impact on the
outcome of FMT in IBD was not mentioned in the infor-
mation sheet; therefore, this additional information could
have changed the patients’ decision on the kind of donor
that the patient would accept.
When questioned about being sure about their decision
to undergo FMT, the majority of patients stated that they
were unsure about their decision (49.1%). This is most
probably because of the fact that a written questionnaire
only includes limited information compared with discus-
sion with a specialist. This is underlined by the fact that
48.4% of the patients stated that after completing the
questionnaire, they were not aware of the advantages and
disadvantages of FMT. Furthermore, 58.9% answered
that they did not have enough support and advice to make
a decision. This shows that only written information is not
enough to enable a patient to make a decision about
treatment options and a direct physician-to-patient contact
is essential to build up a level of conﬁdence, especially for
this type of treatment. This is also underlined by the fact
that the majority of patients (50.7%) stated that a detailed
discussion with a specialist would probably change their
opinion about FMT. However, further understanding of
the knowledge, attitude, and behavior of specialist toward
FMT is needed.
Interestingly, no signiﬁcant differences were observed
between women and men, UC and CD patients, or patients
with a mild or a severe disease course. However, sig-
niﬁcantly more TNF-experienced patients agreed to undergo
FMT after completing the questionnaire compared with
TNF-naive patients. This suggests that patients who are
more therapy experienced could be more interested in FMT.
However, one would expect this to correlate with the
comparison of a mild versus a severe disease course of IBD
as patients with a severe disease course may have a higher
probability of being TNF experienced. Unfortunately, when
comparing the patients with a mild versus a severe disease
course, we could not ﬁnd a statistically signiﬁcant difference
(P=0.38). This may be because of the fact that many phy-
sicians use anti-TNF treatments earlier in the disease course
(a so-called ‘top-down’ therapy). Furthermore, the question
on the disease course was answered by a patient who may
not have been subjected to a direct comparison of his/her
own disease course with other patients. Also, we lack
information on whether the TNF-experienced patients
responded to anti-TNF therapy or whether they were non-
responders (primary nonresponders or secondary loss of
response); this information may have had an impact on the
results of our study. The fact that we could not observe
differences between UC and CD patients is probably because
of the lack of an explanation on the current differences
between CD and UC in the information sheet in terms of
published evidences on FMT.
Furthermore, signiﬁcantly more patients mentioned that
they would consider FMT as a possible treatment option
after reading the one-page patient information and com-
pleting the questionnaire. This suggests that patients might
indeed be highly interested in FMT as a novel IBD treat-
ment, but are currently lacking sufﬁcient information on
how it is performed and its possible risks and beneﬁts.
Our study has several strengths, but also limitations.
We have presented the data from a large cohort of 574
IBD patients. A major strength is that the data have been
gathered prospectively. Further, because of the fact that
the data have been obtained from patients who are part of
a nationwide patient support group, our data not only
reﬂect the ﬁndings of tertiary referral centers but rather
those from a general population. The response rate of our
questionnaire was 31.4%. This study represents the ﬁrst
analysis of our group within the SMCCV. Another ana-
lysis of our group in the Swiss Inﬂammatory Bowel Disease
Cohort Study (SIBDCS), which was published recently,
investigated pain in IBD [46]. In this study, we had a
higher response rate of 59%. The higher response rate in
this cohort may be because of the fact that patients of the
SIBDCS are used to receiving follow-up questionnaires on
a yearly basis and are reminded to send the questionnaire
back if there is no reply. This does not apply to the
SMCCV. Furthermore, pain might be a bigger issue for
IBD patients, given the fact that 71% of patients reported
pain in the SIBDCS. However, it is noteworthy that
patients ﬁlled out the questionnaire anonymously and
were not in the real situation of decision making about
possible FMT, making it only a hypothetical option. In the
actual situation, their decision may be different. In addi-
tion, FMT is still at an experimental stage for IBD and has
not found its way into the different international treatment
recommendations for IBD and is not approved, apart from
CDI, by the Food and Drug Administration [20,29,30]. In
addition, considering that for a majority of patients a
detailed discussion with a specialist is of great importance
for the decision making in terms of FMT, further under-
standing of the knowledge, attitude, and behavior of spe-
cialists toward FMT is needed. Furthermore, patients who
had undergone FMT were not excluded from the study/
analyses; we, therefore, do not have information on the
number and the outcome of FMT in these patients.
However, as FMT is not approved as a treatment option
for IBD in Switzerland, we do not believe that this aspect
affects the results of our analysis. Another limitation of the
study is that we did not include capsules as an option for
FMT. Considering that capsules (besides NGT) represent
another alternative administration route of FMT through
the oral route as an alternative to the lower gastro-
intestinal route, inclusion of this alternative could have
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inﬂuenced the outcome of our study. Also, we used a
nonvalidated questionnaire for our study.
In summary, we have shown that FMT represents a ther-
apeutic procedure that is of interest for patients with IBD. The
knowledge of successful FMT treatments in other IBD patients
is very important for the patients and a detailed discussion
with a specialist seems to be important for the decision making
on FMT. As FMT is receiving increasing attention as an
alternative treatment in IBD and more studies on FMT in IBD
are being carried out, it is important to determine the
knowledge, attitude, and preferences of patients and health-
care providers to provide better education on this topic.
However, there are reservations because of the fact that FMT
is only an experimental treatment option in IBD and several
limitations on the use of FMT in IBD exist.
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